Index

Note: Page numbers in italic denote figures, those in bold denote tables.

ACR (American College of Radiology), implementation of screening programmes 252
adenocarcinoma  see also oesophageal cancer
cervical cancer 86, 93
colorectal cancer 192
incidence 309
lung cancer 223
oesophageal cancer 310
prostate cancer 178
advances to carry forward cancer prevention 417–423
screening 417–423
aflatoxin, hepatocellular carcinoma (HCC) 319
age distribution
breast cancer 113–116, 113
oesophageal cancer 310–311
ovarian cancer (OC) 332
air pollution  see pollution, air
alcohol consumption
breast cancer 123–124
cancer risk 395
hepatocellular carcinoma (HCC) 320
International Agency for Research on Cancer (IARC) 3–4
oral cancer 304
preventable cause of cancer 3–4
5-alpha-reductase inhibitors (5-ARIs), prostate cancer 149–152
American College of Radiology (ACR), implementation of screening programmes 252
anal cancer  see also colorectal cancer
eye early detection and treatment 106–107
high-grade squamous intra-epithelial lesions (HSIL) 103–106
HIV 102–107, 102
HPV testing 101–107
HPV vaccination 103
incidence 101–103, 102
primary prevention 103–104
relative risk 101–103, 102
screening and treatment 104–107
screening tests characteristics 106
secondary prevention 104–106
vaccination 103
antiprogestins, breast cancer 120
appropriateness
 genomic data 414
 screening 414
areca nut, oral cancer 303
aromatase inhibitors (AIs), breast cancer 119–120
arzoxafine, breast cancer 119
asbestos, malignant pleural mesothelioma (MPM) 259–263
Ashkenazi Jewish mutations of the BRCA1 and BRCA2 genes 51, 52
aspirin
 breast cancer 120
 ovarian cancer (OC) 338, 339
aspirin, colorectal cancer prevention 190–198
biological mechanism of aspirin 192–193
dose and duration 195–196
gene expression 194–195
general and high-risk populations 195
germline variants 193–194
personalized chemoprevention 192–195
recommendations and considerations 196–197
somatic mutations 194–195
ataxia telangiectasia, genetic predisposition 304–305
automated whole-breast ultrasound (AWBUS) 138–139
autonomy
 genomic data 413
 screening 412
awareness-raising, cancer prevention 72–79
AWBUS (automated whole-breast ultrasound) 138–139
Beckwith-Wiedemann syndrome (BWS), paediatric cancer 370
benefit optimization
genomic data 413–414
risk information 413–414
screening 413–414
benefits, screening
assessment 34–36
benefits vs risks 41–47
magnitude 38–39
beta-carotene supplements
cancer risk 396
tobacco smoking 396
betel quid, oral cancer 303
biallelic mismatch repair deficiency (bMMRD) syndrome, paediatric cancer 372–373
biases
biopsy bias, PCPT, prostate cancer 150–151
screening test 301
testicular germ cell tumour (TGCT), testicular biopsy 351–352
TRUS-guided prostate biopsy, prostate cancer screening 177
bisphosphonates, breast cancer 120
black and ethnic minority populations
cervical screening 53
ethical issues 55
hepatocellular carcinoma (HCC) 53
oesophageal cancer 53
prostate cancer 53–54
screening 51–55
Bloom's syndrome, genetic predisposition 304–305
BMI see body mass index
bMMRD (biallelic mismatch repair deficiency) syndrome, paediatric cancer 372–373
body mass index (BMI) see also overweight and obesity
cancer association 386–389
BRCA1 and BRCA2 genes, ovarian cancer (OC) 332
breast cancer
see also breast screening
age distribution 113–116, 113
alcohol consumption 123–124
antiprogestins 120
aromatase inhibitors (AIs) 119
arzoxafine 119
aspirin 120
bisphosphonates 120
chemoprevention (preventive therapy) 116–121
cancer association 386–389
exercise 123
familial risk factors 112, 114
lifestyle choices 121–124
metformin 120
nonfamilial breast cancer 112
oestrogen receptor-negative tumours 121
predicting 115
prevention 111–125
preventive therapy (chemoprevention) 116–121
raloxifene 113, 116–118, 122
side effects of preventive therapy 118–119
tamoxifen 113–114, 116–119, 121, 122
weight control 122–123
biopsy bias, PCPT, prostate cancer 150–151
negative biopsy cohort, clinical trials, prostate cancer 158
screening test 301
testicular germ cell tumour (TGCT), testicular biopsy 351–352
TRUS-guided prostate biopsy, prostate cancer screening 177
breast screening 11, 35, 129–141
see also breast cancer
advances to carry forward 419
age impact 131
aims 58
Ashkenazi Jewish mutations of the BRCA1 and BRCA2 genes 51, 52
automated whole-breast ultrasound (AWBUS) 138–139
benefits vs harms 132–133
benefits vs risks 43
breath testing 140–141
Cancer Care Ontario (CCO) 25–28
contrast-enhanced digital mammography (CEDM) 139–140
countries’ implementation 133–136
digital breast tomosynthesis (DBT) 136–138
evidence for the benefit 129–132
individualized screening 136
magnetic resonance imaging (MRI) 140
observational studies 131
opportunistic screening 134, 136
organized screening programmes 133–134
overdiagnosis 132–133
randomized controlled trials (RCTs) 129–131
technologies 136–140
volatile organic compounds (VOC) 140–141
breath testing
breast screening 140–141
malignant pleural mesothelioma (MPM) 268
volatile organic compounds (VOC) 138140–141
BWS (Beckwith-Wiedemann syndrome), paediatric cancer 370
CA-125 (serum CA-125), malignant pleural mesothelioma (MPM) 263
Canada see Cancer Care Ontario (CCO)
Cancer Awareness Measure surveys 70, 72
Cancer Awareness Roadshow, cancer prevention 75–76
Cancer Care Ontario (CCO) 19–28
Canadian Cancer Society (CCS) 24–25
cancer prevention 21–25
cancer system performance 21
federal level 20
health care in Canada 19–20
individual level 23
Ontario Cancer Plan 21
policy work 21–23
prevention research 24
provincial level 20–21
screening programmes 25–28
cancer control strategy
National Cancer Control Programmes (NCCPs) 2, 8, 21
screening 2
cancer fatalism, screening 61
cancer fear, screening 60–61
cancer predisposition syndromes (CPSs), paediatric cancers 361–364
cancer prevention
see also chemoprevention; dietary approaches, cancer prevention; primary prevention; secondary prevention; individual cancers
advances to carry forward 417–423
attitudes towards 70–71
awareness-raising 72–79
Cancer Awareness Measure surveys 70, 72
Cancer Awareness Roadshow 75–76
Cancer Care Ontario (CCO) 21–25
Cancer Research UK 70, 71, 72, 74–79
case study 74–77
controversies, skin cancer 279–282
dietary approaches 381–400
face-to-face intervention 75–76
fatalistic attitudes 70–71
improving understanding 72–79
lifestyle choices 70, 71, 183–185
the media 74–75
online information 74
overweight and obesity 381–389, 397–400
paediatric cancers 362
positive attitudes 70, 71
preventable causes of cancer 2–4
prevention opportunities, lung cancer 222–230
prevention research 24
public understanding 69–79
risk, perceptions of cancer risk 60
risk communication 77–79
skin cancer, controversies 279–282
Talk Cancer training 76–77
‘teachable moments’ 73
training for health workers 76–77
Cancer Research UK
Cancer Awareness Roadshow 75–76
cancer prevention 70, 71, 72, 74–79
infographic 78
Talk Cancer training 76–77
training for health workers 76–77
cancer risk
alcohol consumption 395
beta-carotene supplements 396
cereals (grains) 394
coffee 395
fats and oils 394
fish consumption 394
fruits 393–394
grains (cereals) 394
herbs 393–394
legumes (pulses) 393–394
macronutrients 389–394, 390–392
cancer risk (cont’d)

- meat consumption 389–393
- micronutrients 395–396
- milk and dairy products 394
- nuts 393–394
- oils and fats 394
- plantains 394
- pulses (legumes) 393–394
- roots 394
- salt 394
- seeds 393–394
- spices 393–394
- sugars 394
- tubers 394
- vegetables 393–394

CARCINOMA IN SITU (CIS), TESTICULAR GERM CELL TUMOUR (TGCT) 350, 351–352

CARDIOVASCULAR DISEASE (CVD), PAEDIATRIC CANCERS 376

CASE-CONTROL STUDIES, MELANOMA SCREENING 283–284

CASE STUDY, CANCER PREVENTION 74–77

CAUSES OF CANCER, PREVENTABLE 2–4

CAUTION Mnemonic (seven warning signs), early diagnosis 11

CCO (Cancer Care Ontario)

CEDM (contrast-enhanced digital mammography) 139

CEREALS (GRAINS), CANCER RISK 394

CERVICAL CANCER/Screening 12, 81–97

- abnormal cervical cancer screening tests and cancer precursors 93–95
- adenocarcinoma 86, 93
- advances to carry forward 419
- aims 58
- appropriateness reasons 82
- benefits vs risks 42
- biomarkers 91–93
- black and ethnic minority populations 53
- Cancer Care Ontario (CCO) 25–28
- cytological screening 83–89
- dilemmas 93–95
- effect of screening 86
- HPV (human papilloma virus) 103–106
- HPV testing 42, 89–93
- HSIL (high-grade squamous intra-epithelial lesions) 103–106
- incidence of cervical cancer 83–86
- International Agency for Research on Cancer (IARC) 84, 85, 89
- methods 82–83
- molecular-based technologies 89–93
- problems 84–86
- risk assessment 95–96
- Scandinavian countries 83–84, 86
- sensitivity 86–92
- specificity 86–92
- strategies risk assessment 95–96

- success, factors influencing 86–89
- triage 91–93

CHEMILUMINESCENCE, SCREENING TEST 299–300

CHEMOPREVENTION (PREVENTIVE THERAPY)

- advances to carry forward 419
- breast cancer 116–121
- clinical trial programme 160–163, 164
- colorectal cancer, aspirin 192, 194
- hepatocellular carcinoma (HCC) 323
- lung cancer 230–231
- oral cancer 305
- prostate cancer 148–154, 160–163, 164
- chest X-ray, malignant pleural mesothelioma (MPM) 260–261

CHILDHOOD CANCERS SEE PAEDIATRIC CANCERS

CHROMOSOMAL INSTABILITY PATHWAY, COLORECTAL CANCER 190, 191

CHRONIC INFLAMMATION OF THE PROSTATE, PROSTATE CANCER 147

CIRCULATING TUMOUR DNA (ctDNA), SCREENING 375

CIRCUMCISION 96–97

CIS (CARCINOMA IN SITU), TESTICULAR GERM CELL TUMOUR (TGCT) 350, 351–352

CLINICAL TRIALS, PROSTATE CANCER 156–164

- see also randomized controlled trials (RCTs)
- active surveillance cohort 159, 164
- chemoprevention clinical trial programme 160–163, 164
- HGPIN cohort 157–158
- negative biopsy cohort 158
- pre-prostatectomy cohort 164
- study cohorts 157
- study design 157
- trial end-points 156–157

CMMRD (CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY), PAEDIATRIC CANCERS 373

COFFEE, CANCER RISK 395

COLONSCOPY

- challenges for the future 210
- colorectal cancer screening 12, 205
- effectiveness 208–210
- vs fecal occult blood testing (FOBT) 12
- quality 210
- sigmoidoscopy 209

COLORECTAL CANCER SEE ALSO ANAL CANCER

- adenocarcinoma 192
- chromosomal instability pathway 190, 191
- consensus molecular subtype classification 188, 189, 191

DNA MISMATCH REPAIR PATHWAY 189, 189

FAMILIAL COLORECTAL CANCER TYPE X (FCCTX) 186

FAMILIAL RISK FACTORS 185–188

- genes with predisposing mutations 187
- genetic architecture 185–190, 191
- genetic variants 185–188
- lifestyle risk factors 183–185
- meat 389–393
Index

mutations 185–188
red meat 389–393
risk 183–184
risk alleles 186
colorectal cancer prevention 183–199
aspirin 190–199
future work 197–198
immunological approaches 197–198
lifestyle modifications 190, 192
novel therapies 197–198
strategies 190–192
colorectal cancer screening 12, 203–214
see also fecal immunochemical testing; fecal occult blood testing
advances to carry forward 419
aims 58
benefits vs risks 44–45
Cancer Care Ontario (CCO) 25–27
challenges for the future 214
colonoscopy 12, 205, 208–210
endoscopy 12, 45, 205
evidence overview 204
guidelines 212–214
post-polypectomy surveillance 211–212
rationale for CRC screening 204–205
sigmoidoscopy 45, 207, 209
strategies 212–214
surveillance 211–212
targets of screening 204–205
commonly diagnosed cancers 6
computed tomography (CT), malignant pleural mesothelioma (MPM) 261–262
consent
 genomic data 412
 screening 412
constitutional mismatch repair deficiency (CMMRD), paediatric cancer 373
contrast-enhanced digital mammography (CEDM) 139–140
cost, skin cancer 278–279
cost-effectiveness, lung cancer screening 250–251
CPSs (cancer predisposition syndromes), paediatric cancers 362–364
CT (computed tomography), malignant pleural mesothelioma (MPM) 261–262
circulating tumour DNA (ctDNA), screening 375
CVD (cardiovascular disease), paediatric cancers 376
cytological screening, cervical screening 83–89
data security
 genomic data 412
 screening 412
DBT (digital breast tomosynthesis) 136–138
definition of positive scan, false-positive examinations 245–246
dermoscopy, melanoma screening 288–289
diabetes, hepatocellular carcinoma (HCC) 320
diagnosis
 commonly diagnosed cancers 6
eye diagnosis 11, 14–15
DICER1 syndrome, paediatric cancer 372–373
diet and nutritional factors, oral cancer 304
dietary approaches, cancer prevention 381–400
see also overweight and obesity
dietary patterns 382–384, 396
energy adjustment 382–384
legislation 397–399, 400
macronutrients, cancer risk 389–394
Manchester Cancer Prevention strategy grid 397, 398–399
measurement errors 384
meat consumption 389–393
study design 384–385
weight control 397–399, 400
World Cancer Research Fund (WCRF) 397
dietary contaminants, preventable cause of cancer 4
dietary supplements, prostate cancer 154–156
digital breast tomosynthesis (DBT) 136–138
DNA analysis, screening test 302
DNA mismatch repair pathway, colorectal cancer 189, 189
drugs, ovarian cancer (OC) 337, 337
EAC see adenocarcinoma; oesophageal cancer
early detection and treatment, anal cancer 106–107
early diagnosis 14–15
seven warning signs (CAUTION mnemonic) 11
elastic scattering spectroscopy, screening test 300
electronic cigarettes 421
endometriosis, ovarian cancer (OC) 338
endoscopy, colorectal cancer screening 12, 45, 205
engagement, screening 64–65
epidemiological factors
hepatocellular carcinoma (HCC) 317
ovarian cancer (OC) 333–337
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidance 384–385
equity
 genomic data 414
 screening 414
ethical issues
black and ethnic minority populations 55
 genetic testing, ethics, paediatric cancers 373–374, 410–414
 genomic data 373–374, 410–414
 screening 55, 373–374, 410–414
HA (hyaluronic acid), malignant pleural mesothelioma (MPM) 263

harms of screening see benefits vs harms, screening

HBC (hepatitis C virus), hepatocellular carcinoma (HCC) 319, 321

HBV (hepatitis B virus)
hepatocellular carcinoma (HCC) 319, 321–322
primary prevention 6
HCC see hepatocellular carcinoma (HCC)
hepatitis B virus (HBV) see HBV (hepatitis B virus)

hepatitis C virus (HBC) see HBC (hepatitis C virus)

hepatocellular carcinoma (HCC) 317–327
aflatoxin 319
alcohol consumption 320
black and ethnic minority populations 52–53
chemoprevention (preventive therapy) 322
definition 317–318
diabetes 320
effectiveness of treating early disease 323
epidemiological factors 317–318
HBC (hepatitis C virus) 319, 321
HBV (hepatitis B virus) 319, 321–322
hereditary haemochromatosis (HH) 319
lifestyle modifications 322
liver cirrhosis 318
metabolic syndrome 320
overweight and obesity 320
risk factors 318–319
risk reduction 320–322
tobacco smoking 320
viral hepatitis 321–322

hepatocellular carcinoma (HCC) screening
blood-based tests 324–325
cost-effectiveness 326–327
effectiveness of screening 324–327
effectiveness of treating early disease 323
imaging 324
screening 53, 323–326
screening methodology 324–325
target population for screening 323–324
ultrasound (US) screening 324

herbs, cancer risk 393–394
hereditary haemochromatosis (HH), hepatocellular carcinoma (HCC) 319
HH (hereditary haemochromatosis), hepatocellular carcinoma (HCC) 319
high-grade squamous intra-epithelial lesions (HSIL), anal cancer 103–106
high-mobility group protein B1 (HMGB-1), malignant pleural mesothelioma (MPM) 262–263

high-penetrance genes, ovarian cancer (OC) 332–333
HIV, anal cancer 102–107, 102
HMGB-1 (high-mobility group protein B1), malignant pleural mesothelioma (MPM) 262–263

hormone replacement therapy, ovarian cancer (OC) 337–338
HPV (human papilloma virus) testing
algorithms 91
anal cancer 101–107
cervical cancer/screening 42, 89–93, 103–106
HPV infection and testing, anal cancer 101–107
HPV vaccination, anal cancer 103
oral cancer 304
primary prevention 6–8
HSIL (high-grade squamous intra-epithelial lesions)
alan cancer 103–106
cervical screening 103–106
human papilloma virus see HPV testing
hyaluronic acid (HA), malignant pleural mesothelioma (MPM) 263

IARC see International Agency for Research on Cancer
IDLE (indolent lesion of epithelial origin), melanoma screening 286
ILK (integrin-linked kinase), malignant pleural mesothelioma (MPM) 266, 269
immunological approaches, colorectal cancer prevention 197–198
incidence
adenocarcinoma 309
anal cancer 101–103, 102
cervical cancer 83–86
lung cancer 219–221, 220, 219, 222
malignant pleural mesothelioma (MPM) 258
melanoma 276–278, 277
oral cancer 295–296
skin cancer 276–278
squamous cell cancer (SCC) 309
testicular germ cell tumour (TGCT) 349–350
incidence trends, melanoma 278
indolent lesion of epithelial origin (IDLE), melanoma screening 286
indolent lesions 36
melanoma screening 285–286
prostate cancer 11, 13, 150, 172, 173
infections, preventable cause of cancer 3
informed choice, screening 62–63
informed decision-making, screening 46–47
inhaled agents, lung cancer 218–219
integrin-linked kinase (ILK), malignant pleural mesothelioma (MPM) 266, 269
intention and action, screening 63–64
intention–behaviour gap, screening 63
International Agency for Research on Cancer (IARC)
alcohol consumption 3–4
cervical screening 84, 85, 89
lung cancer 4, 222
meat 389–393
melanoma 277
overweight and obesity 4, 386, 387, 389
International Agency for Research on Cancer (IARC) \( \text{(cont’d)} \)
pollution, air 4, 226–227
red meat 389–393
sunscreen 280
tobacco smoking 219
ionizing radiation
gamma-rays 220
lung cancer 227–229
radiation risk, lung cancer screening 246–247
radon 228–229
X-rays 229, 260–261

justice
genomic data 414
screening 414

kallikreins 176

lab-on-a-chip, screening test 302
lasofoxafine, breast cancer 119
late presentation, reasons 14–15
lead-time bias, screening 34
legal aspects
genomic data 410–415
screening 410–415
legislation, dietary approaches, cancer prevention 397–399, 400
legumes (pulses), cancer risk 393–394
length bias, screening 34
LFS (Li-Fraumeni syndrome), paediatric cancer 365
lifestyle choices
breast cancer 121–124
cancer prevention 70, 71, 183
oesophageal cancer 314
lifestyle factors, ovarian cancer (OC) 337
lifestyle modifications, hepatocellular carcinoma (HCC) 322
lifestyle risk factors
colorectal cancer 183
oesophageal cancer 311
Li-Fraumeni syndrome (LFS), paediatric cancer 365
light-based detection systems, screening test 299–301
liver cancer see hepatocellular carcinoma (HCC)
liver cirrhosis, hepatocellular carcinoma (HCC) 318
low-penetrance inherited genetic variants, ovarian cancer (OC) 333
Lugol’s iodine, screening test 299
lung cancer 217–233
adenocarcinoma 223
advances to carry forward 421–422
biomass fuel burning 227
burden of avoidable lung cancer 231–232
causes 222–230
chemoprevention (preventive therapy) 230–231
gamma-rays 220
incidence 219–221, 220, 219, 222
inhaled agents 218–219
International Agency for Research on Cancer (IARC) 4, 222
ionizing radiation 227–229
mortality 221, 219, 222
occupational factors 229–230
occurrence 219–221, 222
pollution, air 4, 218–219, 226–227
prevention opportunities 222–230
primary prevention 218
radon 228–229
risk factors 217–219, 231–232, 229, 230
secondary prevention 218
tobacco smoking 222–226
X-rays 229, 260–261
lung cancer screening 13, 35, 38, 237–252
aims 58
cost-effectiveness 250–251
early approaches 238
European Randomized Controlled Trials (EUCT) 239–244, 240–243
false-positive examinations 245–246, 250
implementation of screening programmes 251–252
overdiagnosis 239
populations selection 248–250, 249
radiation risk 246–247
randomized controlled trials (RCTs) 238–244
recommendations for screening 247–248
screening in never smokers 250
smoking cessation programmes 251
tobacco smoking 251
Lynch syndrome, ovarian cancer (OC) 333
macronutrients, cancer risk 389–394, 390–392
magnetic resonance imaging (MRI), breast screening 140
malignant pleural mesothelioma (MPM) 257–269
asbestos 259–263
biomarkers 262–268, 269
breath testing 268
CA-125 (serum CA-125) 263
chest X-ray 260–261
computed tomography (CT) 261–262
fibulin-3 265–266, 269
high-mobility group protein B1 (HMGB-1) 262–263
hyaluronic acid (HA) 263
identifying at-risk population 259
incidence 258
integrin-linked kinase (ILK) 266, 269
megakaryocyte-potentiating factor (MPF) 264–265, 269
microRNAs (miRNAs) 267
osteopontin (OPN) 265, 269
prevalence 258
screening 257–269
screening methodologies 259–268
screening role 257–258
screening tests requirements 258
serum CA-125 263
soluble mesothelinrelated protein (SMRP) 263–264, 269
SOMAmer (Slow Off-rate Modified Aptamer) reagents 266–267
mammography see breast screening
Manchester Cancer Prevention strategy grid, dietary approach 397, 398–399
mastectomy 124
meat
colorectal cancer 389–393
International Agency for Research on Cancer (IARC) 389–393
meat consumption, cancer risk 389–393
the media, cancer prevention 74–75
megakaryocyte-potentiating factor (MPF), malignant pleural mesothelioma (MPM) 264–265, 269
melanoma
see also skin cancer
causes 276
incidence 276–278, 277
incidence trends 278
International Agency for Research on Cancer (IARC) 277
mortality 277
risk factors 276
melanoma screening 282–289
case-control studies 283–284
depth distribution studies 285
dermoscopy 288–289
indolent lesion of epithelial origin (IDLE) 286
indolent lesions 285–286
malignant vs benign lesions 287–288
overdiagnosis 285–286
patient management 287–289
population-based comparisons 284
randomized controlled trials (RCTs) absence 282–283
recommendations of major groups 283
risk-prediction models 286–287
SCREEN programme, Germany 284–285
selective screening 286–287
Spectrophotometric Intracutaneous Analysis (SIAcopy) scanner 288–289
MEN (multiple endocrine neoplasia), paediatric cancer 369–370
mesothelioma see malignant pleural mesothelioma
metabolic syndrome, hepatocellular carcinoma (HCC) 320
metformin
breast cancer 120
prostate cancer 153
microendoscopy, screening test 300
Mircrolux/DL®, screening test 300
micronutrients, cancer risk 395–396
microRNAs (miRNAs), malignant pleural mesothelioma (MPM) 267
microscopy, screening test 301, 302
milk and dairy products, cancer risk 394
miRNAs (microRNAs), malignant pleural mesothelioma (MPM) 267
moderate-penetrance genes, ovarian cancer (OC) 333
molecular-based technologies, cervical screening 89–93
mortality
lung cancer 221, 219, 222
melanoma 277
oral cancer 295–296
ovarian cancer (OC) 340–341
mouth self-examination (MSE), oral cancer 297–298
MPF (megakaryocyte-potentiating factor), malignant pleural mesothelioma (MPM) 264–265, 269
MPM see malignant pleural mesothelioma
MRI (magnetic resonance imaging), breast screening 140
MSE (mouth self-examination), oral cancer 297–298
multiple endocrine neoplasia (MEN), paediatric cancer 369–370
multispectral digital microscope, screening test 302
nano-particles, screening test 302
narrow-band imaging, screening test 301
National Cancer Control Programmes (NCCPs) cancer control strategy 2, 8–9
review 21
National Lung Screening Trial (NLST) 238–239
vs European Randomized Controlled Trials (EUCT) 244
NCCPs see National Cancer Control Programmes neuroblastoma, screening 36
nevoid basal cell carcinoma syndrome (Gorlin syndrome), paediatric cancer 372
next-generation sequencing (NGS) advances to carry forward 422–423
genetic predisposition 406, 409
screening 374–375
NLST (National Lung Screening Trial) 238–239
nodule management, false-positive examinations 245–246
nodule measurement, false-positive examinations 245–246
novel therapies, colorectal cancer prevention 197–198
nutrition see diet...
nuts, cancer risk 393–394

obesity see overweight and obesity
OC see ovarian cancer (OC)/screening
occupational factors, lung cancer 229–230
occupational health, primary prevention 8
occupations, preventable cause of cancer 4
oesophageal cancer 309–315
see also adenocarcinoma
adenocarcinoma 310
black and ethnic minority populations 53
future perspectives 313–314
gastro-oesophageal reflux disease (GORD) 311
genetic predisposition 311
global perspective 309–310
lifestyle choices 314
lifestyle risk factors 311
overweight and obesity 311
prevention 311–315
risk factors 310–311
screening 52, 311–315
sex, risk factor 311
surveillance 312–313
oestrogen receptor–negative tumours, breast cancer 121
oils and fats, cancer risk 394
online information, cancer prevention 74
Ontario see Cancer Care Ontario (CCO)
OPN (osteopontin), malignant pleural mesothelioma (MPM) 265, 269
optical coherence tomography, screening test 300
oral cancer 295–306
alcohol consumption 304
areca nut 303
betel quid 303
chemoprevention (preventive therapy) 305
diet and nutritional factors 304
genetic predisposition 304–305
health workers’ role 296–297
HPV (human papilloma virus) 304
incidence 295–296
mortality 295–296
mouth self-examination (MSE) 297–298
prevention 302–306
primary care clinicians’ role 296–297
screening 296–302
screening guidelines 297
screening tests 298–302
smokeless tobacco 303
tobacco smoking 303–304
oral contraceptive pill, ovarian cancer (OC) 340
osteopontin (OPN), malignant pleural mesothelioma (MPM) 265, 269
ovarian cancer (OC)/screening 331–343
advances to carry forward 420
age distribution 332
aspirin 338, 339
BRCA1 and BRCA2 genes 332
drugs 337–338
dometriosis 338
epidemiological factors 333–337
familial risk factors 332–333
genetic predisposition 333
high-penetrance genes 332–333
hormone replacement therapy 337–338
lifestyle factors 337
lifetime risk 332
low-penetrance inherited genetic variants 333
Lynch syndrome 332
moderate-penetrance genes 333
mortality 340–341
oral contraceptive pill 340
prevention 339–340
randomized controlled trials (RCTs) 340
risk factors 332–338, 334–337
risk-prediction models 338–339
risk-reducing salpingo-oophorectomy (RRSO) 339
risk-reducing surgery 338–339
screening 340–343
screening future directions 342
screening general population 340–341
screening high-risk women 342
statins 338
symptom awareness 342–343
overdiagnosis
advances to carry forward 420
breast screening 132–133
lung cancer screening 239
melanoma screening 285–286
prostate cancer 408
overweight and obesity
see also diet...
advances to carry forward 418
body mass index (BMI), cancer association 386–389
cancer prevention 381–389, 397–400
hepatocellular carcinoma (HCC) 320
International Agency for Research on Cancer (IARC) 4, 386, 387, 389
obesity-related cancers 386, 387
oesophageal cancer 311
population-attributable risk 389
preventable cause of cancer 4
prostate cancer 148
paediatric cancers 361–377
Beckwith-Wiedemann syndrome (BWS) 370
biallelic mismatch repair deficiency (bMMRD) syndrome 373
cancer predisposition syndromes (CPs) 361–363
cancer prevention 362–363
cardiovascular disease (CVD) 375–376
constitutional mismatch repair deficiency (CMMRD) 373
DICER1 syndrome 372–373
familial adenomatous polyposis (FAP) 368–369
genetic testing, ethics 373–374
germline TP53 mutations 365, 366, 367
hereditary PHEO/PGL (chronic inflammation of the prostate) 371–372
late effects of treatment 375–376
Li–Fraumeni syndrome (LFS) 365
multiple endocrine neoplasia (MEN) 369–370
nevoid basal cell carcinoma syndrome (Gorlin syndrome) 372
pheochromocytomas and paragangliomas (PHEO/PGL) 371–372
retinoblastoma 367–368
screening 364–365
screening, future directions 374–375
screening, genetic testing, ethics 373–374
secondary neoplasms 375
surveillance 365, 366, 367
von Hippel-Lindau (VHL) disease 371
perceptions of cancer risk 60
pheochromocytomas and paragangliomas (PHEO/PGL), paediatric cancers 371–372
PHEO/PGL (pheochromocytomas and paragangliomas), paediatric cancers 371–372
physical agents, preventable cause of cancer 4
plantains, cancer risk 394
pollution, air
advances to carry forward 418
biomass fuel burning 227
International Agency for Research on Cancer (IARC) 4, 226–227
lung cancer 4, 218–219, 226–227
preventable cause of cancer 4
population-attributable risk, overweight and obesity 389
population-based comparisons, melanoma screening 284
populations screened 37–38
populations selection
false-positive examinations 250
lung cancer screening 248–250, 249
risk-based models 248–250, 249
positive predictive value, screening 33–34
Precaution Adoption Process Model, screening 64
predicting breast cancer 114–116
prevalence, prostate cancer 146
prevalence of cancer 2–4, 3
preventable causes of cancer 2–4
prevention, cancer see cancer prevention
preventive therapy see chemoprevention
primary prevention 5–8
anal cancer 103–104
goals 218
HBV (hepatitis B virus) 6
human papilloma virus (HPV) 6–8
lung cancer 218
occupational health 8
tobacco smoking 5
vaccination 5–8
privacy
genomic data 412
screening 412
prostate cancer 145–165
see also clinical trials, prostate cancer; prostate cancer screening
adenocarcinoma 177
5-alpha-reductase inhibitors (5-ARIs) 149
biopsy bias, PCPT 150–151
chemoprevention (preventive therapy) 148–154, 160–163
chronic inflammation of the prostate 147
clinical trials 156–165
dietary supplements 154–156
effective treatments 174–175
genetic predisposition, risk prediction 407–408, 408
importance 173
indolent lesions 11, 13, 150, 172, 173
management 146
metformin 153
natural history 173–174
overdiagnosis 408
overweight and obesity 148
prevalence 146
prevention 145–165
preventive therapy (chemoprevention) 148–154, 160–163
Prostate Cancer Prevention Trial (PCPT) 149–150
PSA bias, PCPT 150
rationale for prevention 146
Reduction by Dutasteride of Prostate Cancer Events Trial (REDUCE) 151–152
risk factors 146–147
risk prediction, genetic predisposition 407–408, 408
selenium and vitamin E 154–156
statins 153–154
tobacco smoking 147–148
treatments, effective 174–175
vitamin E and selenium 154–156
Prostate Cancer Prevention Trial (PCPT) 149–151
prostate cancer screening 13, 36, 38, 171–179
abnormal PSA test 177
acceptability of the test 175–177
advances to carry forward 419
aims 58
benefits vs harms 177–178
prostate cancer screening (cont’d)
benefits vs risks 45–46
black and ethnic minority populations 53–54
future developments 179
requirements of a screening programme 9–10, 172
TRUS-guided prostate biopsy 177
psychological harms, screening 46
public awareness
fecal occult blood testing (FOBT) 64
screening 57–65
public understanding, cancer prevention 69–79
pulses (legumes), cancer risk 393–394
radiation risk
see also ionizing radiation
lung cancer screening 246–247
radon, lung cancer 228–229
raloxifene, breast cancer 113, 116–119, 122
randomized controlled trials (RCTs)
see also clinical trials, prostate cancer; evidence
for the benefit of screening
absence in melanoma screening 282–283
breast screening 129–131
European Randomized Controlled Trials (EUCT) 239–244, 240–243
lung cancer screening 238–244
melanoma screening, absence 282–283
National Lung Screening Trial (NLST) 238–239
ovarian cancer (OC) 340–341
red meat
colorectal cancer 389–393
International Agency for Research on Cancer (IARC) 389–393
Reduction by Dutasteride of Prostate Cancer Events Trial (REDUCE), prostate cancer 151–152
registries, cancer burden 417–418
retinoblastoma, paediatric cancer 367–368
risk
perceptions of cancer risk 60
testicular germ cell tumour (TGCT) 349–350, 353–355
risk assessment
cervical screening 95–96
testicular germ cell tumour (TGCT) 353–355
risk-based models, populations selection for screening 248–250, 249
risk communication, cancer prevention 77–79
risk factors
see also cancer risk
evidence criteria 383
familial risk factors, breast cancer 112–116
familial risk factors, colorectal cancer 185–188
hepatocellular carcinoma (HCC) 318–320
lifestyle risk factors, colorectal cancer 183–185
lung cancer 217–219, 231–232, 229, 230
melanoma 276
oesophageal cancer 310–311
ovarian cancer (OC) 332–338, 334–337
prostate cancer 146–148
skin cancer 276
risk information
benefit optimization 413–414
harm minimization 413–414
risk-prediction models
melanoma screening 286–287
ovarian cancer (OC) 338–339
risk-reducing mastectomy (RRM), breast cancer 124–125
risk-reducing salpingo-oophorectomy (RRSO), ovarian cancer (OC) 339
risk-reducing surgery, ovarian cancer (OC) 339
risk reduction, hepatocellular carcinoma (HCC) 320–322
ROCA algorithm 341
roots, cancer risk 394
RRM (risk-reducing mastectomy), breast cancer 124
RRSO (risk-reducing salpingo-oophorectomy), ovarian cancer (OC) 339
salivary biomarkers, screening test 301
salt, cancer risk 394
Scandinavian countries, cervical screening 83–84, 86
SCC see squamous cell cancer screening 9–14
see also specific cancers
advances to carry forward 417–423
aims 58
anal cancer screening 104–107
appropriateness 414
autonomy 412–413
beliefs 59–63
benefit assessment 34–36
benefit magnitude 38–39
benefit optimization 413–414
benefits vs risks 41–47
black and ethnic minority populations 51–55
breast screening 11, 25–27, 35, 43, 58
cancer control strategy 2
cancer fatalism 61
cancer fear 60–61
cervical screening 12, 25–27, 42, 53, 58, 81–97
circulating tumour DNA (ctDNA) 375
colorectal cancer screening 12, 25–27, 44–45, 58
consent 412–413
data security 412
Index

definition 296
engagement 64–65
equity 414
ethical issues 55, 373–374, 410–414
evidence for the benefit 10, 27, 36–37
fecal occult blood testing (FOBT) 12, 25–27, 44–45, 58
future directions, paediatric cancers 374–375
gastric cancer screening 13
genetic testing, ethics, paediatric cancers 373–374, 410–414
germline TP53 mutations 375
guidelines 297
harm minimization 413–414
harm minimization 413–414
harms see benefits vs harms, screening
hepatocellular carcinoma (HCC) 53, 323–327
information choice 62–63
informed decision-making 46–47
intention and action 63–64
intention–behaviour gap 63
intervals 10–11
justice 414
lead-time bias 34
legal aspects 410–414
length bias 34
limitations 54, 55
lung cancer screening 13, 35, 38–39, 58
malignant pleural mesothelioma (MPM) 257–269
mass screening 39
melanoma 282–289
misconception 32
neuroblastoma 36
next-generation sequencing (NGS) 374
oesophageal cancer 53, 311–315
options 11–13
oral cancer 296–302
ovarian cancer (OC) 340–343
overdiagnosis 35–36, 62, 132–133, 239, 283–286
paediatric cancers 364–373
perceived benefits and harms 61–62
perceptions of cancer risk 60
populations screened 37–38
positive predictive value 33–34
in practice 39
Precaution Adoption Process Model 64
principles 9–11
privacy 412
prostate cancer screening 13, 36, 38, 45–46, 53–54, 58
psychological harms 46
public awareness 57–65
randomized controlled trials (RCTs) absence 282–283
requirements of a screening programme 9–10, 172
risk, perceptions of cancer risk 60
risks vs benefits 41–47
selection bias 37
selective screening 286–287
sensitivity 33, 86–92
social aspects 410–414
specificity 33, 86–92
’s stage shift’ 10, 130, 238, 258, 296, 341, 420
storage 412
structured programme 39
successful screening 32
targeted screening 14
testicular germ cell tumour (TGCT) 349–357
thyroid screening 36
World Health Organization recommendations 58
screening and treatment, anal cancer 104–107
screening programmes, Cancer Care Ontario (CCO) 25–27
screening tests 298–302, 296
anal cancer, screening tests characteristics 106
assessing a screening test 33
biomarkers 301–302
biopsy 301
cervical screening, abnormal cervical cancer screening tests and cancer precursors 93–95
chemiluminescence 299–300
DNA analysis 302
elastic scattering spectroscopy 300
exfoliative cytology 298–299
lab-on-a-chip 302
light-based detection systems 299–301
Lugol’s iodine 299
malignant pleural mesothelioma (MPM), screening tests requirements 258
microendoscopy 300
Microlux/DL® 300
microscopy 301, 302
multispectral digital microscope 302
nano-particles 302
narrow-band imaging 301
optical coherence tomography 300
oral cancer 298–302
salivary biomarkers 301
serum biomarkers 301
spectral cytopathology 302
spectroscopy 302
tissue fluorescence imaging 300
tissue fluorescence spectroscopy 300
toluidine blue 299
VELscope® system (Visually Enhanced Lesion Scope) 300
Visually Enhanced Lesion Scope (VELscope® system) 300
Vizilite® 299–300
SCREEN programme, Germany, melanoma screening 284–285
secondary neoplasms, paediatric cancers 375
secondary prevention
anal cancer 104–106
goals 218
lum cancer 218
seeds, cancer risk 393–394
selection bias, screening 37
selective screening, melanoma
screening 286–287
seleum and vitamin E, prostate
screening 154–156
semen assay
detection of CIS 352
testicular germ cell tumour (TGCT) 352
serum biomarkers, screening test 301
serum CA-125, malignant pleural mesothelioma (MPM) 263
seven warning signs (CAUTION mnemonic) 2
erly diagnosis 11
sex, risk factor, oesophageal cancer 310
SIAcopy (Spectrophotometric Intracutaneous Analysis) scan, melanoma
screening 288–289
sigmoidoscopy
colonoscopy 209
coloctal cancer screening 45, 207, 209
skin cancer 275–289
see also melanoma
causes 276
cost 278–279
incidence 276–278
prevention controversies 279–282
risk factors 276
solaria ban 281
sunbeds ban 281
dunscreen 280–281
types 275
UVR exposure 276, 279–282
vitamin D 281
Slow Off-rate Modified Aptamer (SOMAmer) reagents, malignant pleural mesothelioma (MPM) 266–267
smokeless tobacco, oral cancer 303
smoking see tobacco smoking
smoking cessation programs, lung cancer
screening 251
SMRP (soluble mesothelin-related protein), malignant pleural mesothelioma (MPM) 263–264, 269
social aspects
genomic data 410–414
screening 410–414
solaria ban, skin cancer 281
soluble mesothelin-related protein (SMRP), malignant pleural mesothelioma (MPM) 263–264, 269
SOMAmer (Slow Off-rate Modified Aptamer) reagents, malignant pleural mesothelioma (MPM) 266–267
spectral cytopathology, screening test 302
Spectrophotometric Intracutaneous Analysis (SIAcopy) scan, melanoma
screening 288–289
spectroscopy, screening test 302
spices, cancer risk 393–394
squamous cell cancer (SCC)
global perspective 309–310
incidence 309
oral cancer 296, 301
skin cancer 276
'stage shift', screening 10, 130, 238, 258, 296, 341, 420
statins
ovarian cancer (OC) 338
prostate cancer 153–154
Stockholm study 179
storage
genomic data 412
screening 412
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidance, study design 384–385
study design
biases 34, 36–37, 384–385
clinical trials, prostate cancer 157
confounding 384–385
dietary approaches, cancer prevention 384–385
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidance 384–385
sugars, cancer risk 394
sunbeds ban, skin cancer 281
sunscreen
International Agency for Research on Cancer (IARC) 280
skin cancer 280–281
surveillance
active surveillance cohort, clinical trials, prostate cancer 159–164
coloctal cancer screening 211–212
oesophageal cancer 312–313
paediatric cancers 365, 366, 367
Talk Cancer training, cancer prevention 76–77
tamoxifen, breast cancer 113–114, 116–119, 121, 122
targeted screening 14
nonspecific symptoms 15
'teachable moments', cancer prevention 73
testicular biopsy
detection of CIS 351–352
testicular germ cell tumour (TGCT) 351–352
testicular germ cell tumour (TGCT) 349–357
carcinoma in situ (CIS) 350, 351–352
detection of CIS 351–352
identifying men at high risk 353–355
incidence 349–350
risk 349–350, 353–355
risk assessment 353–355
risk assessment based on environmental risk factors 353–354
risk assessment based on family history 354
risk assessment based on genetic profile 354–355
risk assessment based on medical history 353
screening 349–357
screening, future directions 356–357
screening, theoretical model 356–357
screening challenges 355
semen assay 352
testicular biopsy 351–352
testicular self-examination (TSE) 350–351
ultrasound (US) screening 351
testicular self-examination (TSE), testicular germ cell tumour (TGCT) 350–351
TGCT see testicular germ cell tumour
thyroid screening 36
tissue fluorescence imaging, screening test 300
tissue fluorescence spectroscopy, screening test 300
tobacco control 223–226
advances to carry forward 418, 421, 422
electronic cigarettes 421
FCTC (Framework Convention on Tobacco Control) 225–226
World Health Organization (WHO) 225–226
tobacco smoking
beta-carotene supplements 396
hepatocellular carcinoma (HCC) 320
International Agency for Research on Cancer (IARC) 219
lung cancer 222–226
lung cancer screening 251
oral cancer 303–304
per capita cigarette consumption 218
preventable cause of cancer 3–4
primary prevention 5
prostate cancer 147–148
smokeless tobacco, oral cancer 303
smoking cessation programmes, lung cancer screening 251
toluidine blue, screening test 299
training for health workers
cancer prevention 76–77
Cancer Research UK 76–77
triage
biomarkers 91–93
cervical screening 91–93
TRUS-guided prostate biopsy, prostate cancer screening 177
TSE (testicular self-examination), testicular germ cell tumour (TGCT) 350–351
tubers, cancer risk 394
ultrasound (US) screening
automated whole-breast ultrasound (AWBUS) 138–139
hepatocellular carcinoma (HCC) 324
testicular germ cell tumour (TGCT) 351
UVR exposure, skin cancer 276, 279–282
vaccination
advances to carry forward 418
anal cancer 103
HPV vaccination 103
primary prevention 5–8
vegetables, cancer risk 393–394
VELscope® system (Visually Enhanced Lesion Scope), screening test 300
VHL (Von Hippel-Lindau) disease, paediatric cancer 371
viral hepatitis, hepatocellular carcinoma (HCC) 320–321
Visually Enhanced Lesion Scope (VELscope® system), screening test 300
vitamin D, skin cancer 281
vitamin E and selenium, prostate cancer 154–156
Vizilite®, screening test 299–300
volatile organic compounds (VOC), breast screening 140
Von Hippel-Lindau (VHL) disease, paediatric cancer 371
weight control
breast cancer 122–123
dietary approaches, cancer prevention 397–399, 400
World Cancer Research Fund (WCRF)
dietary approaches, cancer prevention 397
macronutrients, cancer risk 390–392
risk factors evidence criteria 383
World Health Organization (WHO)
Framework Convention on Tobacco Control (FCTC) 225–226
screening recommendations 58
tobacco control 225–226
X-rays
lung cancer 229, 260–261
malignant pleural mesothelioma (MPM) 260–261